š„ 21st Bio on strains, scale, and the valley of death: Fixing precision fermentationās weak links
Henrik Geertz-Hansen from 21st Bio discusses the challenges and potential of biomanufacturing to compete with petrochemicals and animal products, emphasizing the need for optimized strains, strategic partnerships, and technology advancements to achieve cost parity and scalability in the industry. He highlights the importance of platform technologies, continuous fermentation, and AI in overcoming current bottlenecks and enabling localized, sustainable production.
For someone focused on foodtech and biomanufacturing, the key insight is the emphasis on developing platform technologies and strains that can thrive at industrial scale. This approach aims to streamline the transition from lab-scale to full-scale production, reducing complexity and costs. Companies like 21st Bio are facilitating this by enabling startups to focus on their core innovations while 21st Bio manages the strain optimization and tech transfer, which is critical for scaling precision fermentation to economically compete with traditional animal proteins.